| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 2.01B | 15.28 | 388.80 | 33.97% | 29.28% | 21.28% | 2.19% | 0.21 |
| ARGXargenx SE | 49.26B | 796.00 | 62.28 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.45B | 19.44 | 54 | 15.54% | 32.78% | 12.61% | 12.96% | 0.65 |
| GLPGGalapagos N.V. | 2.18B | 33.11 | 29.56 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.02B | 80.25 | 18.97 | 6.24% | 21.94% | 7.11% | 3.64% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.48B | 21.09 | -2.03 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.13B | 14.47 | -2.74 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.49B | 30.69 | -6.15 | -22.44% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 42.13M | 48.65M | 15.39M | 60.37M | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M | 64.38M |
| Revenue Growth % | 2.6% | 0.15% | -0.68% | 2.92% | 0.22% | -0.02% | -0.23% | -0.07% | 0.12% | 0.12% |
| Cost of Goods Sold | 4.66M | 2.89M | 6.03M | 715K | 0 | 0 | 193.66M | 63.39M | 40.62M | 0 |
| COGS % of Revenue | 0.11% | 0.06% | 0.39% | 0.01% | - | - | 3.5% | 1.23% | 0.71% | - |
| Gross Profit | 37.47M | 45.75M | 9.36M | 59.66M | 73.41M | 71.86M | -138.35M | -12.05M | 16.8M | 64.38M |
| Gross Margin % | 0.89% | 0.94% | 0.61% | 0.99% | 1% | 1% | -2.5% | -0.23% | 0.29% | 1% |
| Gross Profit Growth % | 3.91% | 0.22% | -0.8% | 5.38% | 0.23% | -0.02% | -2.93% | 0.91% | 2.39% | 2.83% |
| Operating Expenses | 219.37M | 226.22M | 269.48M | 298.41M | 325.33M | 369.48M | 119.44M | 79.91M | 72.84M | 111.33M |
| OpEx % of Revenue | 5.21% | 4.65% | 17.51% | 4.94% | 4.43% | 5.14% | 2.16% | 1.56% | 1.27% | 1.73% |
| Selling, General & Admin | 90.2M | 84.51M | 95.59M | 97.06M | 106.08M | 108.53M | 0 | 67.07M | 70.45M | 69.17M |
| SG&A % of Revenue | 2.14% | 1.74% | 6.21% | 1.61% | 1.44% | 1.51% | - | 1.31% | 1.23% | 1.07% |
| Research & Development | 129.16M | 141.71M | 173.89M | 201.35M | 219.25M | 260.95M | 201.55M | 70.07M | 46.34M | 37.64M |
| R&D % of Revenue | 3.07% | 2.91% | 11.3% | 3.34% | 2.99% | 3.63% | 3.64% | 1.36% | 0.81% | 0.58% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -82.11M | -57.24M | -43.96M | 4.51M |
| Operating Income | -181.9M | -180.47M | -260.12M | -238.75M | -251.91M | -297.63M | -257.78M | -91.96M | -56.03M | -46.95M |
| Operating Margin % | -4.32% | -3.71% | -16.91% | -3.95% | -3.43% | -4.14% | -4.66% | -1.79% | -0.98% | -0.73% |
| Operating Income Growth % | 0.22% | 0.01% | -0.44% | 0.08% | -0.06% | -0.18% | 0.13% | 0.64% | 0.39% | 0.16% |
| EBITDA | -178.91M | -177.35M | -256.1M | -235.59M | -245.7M | -290.65M | -252.97M | -88.92M | -54.03M | -43.33M |
| EBITDA Margin % | -4.25% | -3.65% | -16.64% | -3.9% | -3.35% | -4.04% | -4.57% | -1.73% | -0.94% | -0.67% |
| EBITDA Growth % | 0.22% | 0.01% | -0.44% | 0.08% | -0.04% | -0.18% | 0.13% | 0.65% | 0.39% | 0.2% |
| D&A (Non-Cash Add-back) | 2.99M | 3.12M | 4.03M | 3.17M | 6.21M | 6.97M | 4.81M | 3.04M | 2M | 3.62M |
| EBIT | -181.27M | -179.16M | -263.16M | -215.6M | -209.81M | -294.8M | -237.64M | -79.12M | -53.65M | -42.07M |
| Net Interest Income | 631K | -92K | -3.76M | 1.48M | -23.47M | -4.11M | -7.44M | 2.18M | 6.77M | 2.33M |
| Interest Income | 631K | 1.31M | 4.79M | 11.97M | 8.39M | 4.44M | 1.11M | 8.54M | 9.12M | 4.88M |
| Interest Expense | 0 | 1.4M | 8.55M | 10.48M | 31.86M | 8.55M | 8.55M | 6.37M | 2.35M | 2.55M |
| Other Income/Expense | 631K | -92K | -11.59M | 12.67M | 10.24M | -5.72M | -7.44M | -858K | 6.77M | 2.33M |
| Pretax Income | -181.27M | -180.56M | -271.71M | -226.09M | -241.68M | -303.34M | -265.22M | -92.81M | -49.27M | -44.61M |
| Pretax Margin % | -4.3% | -3.71% | -17.66% | -3.74% | -3.29% | -4.22% | -4.8% | -1.81% | -0.86% | -0.69% |
| Income Tax | 951K | 10.11M | 13.69M | -10.56M | -5.22M | -8.52M | -151K | 9K | 5.92M | 11.8M |
| Effective Tax Rate % | 1.01% | 1.06% | 1.05% | 0.95% | 0.98% | 0.92% | 0.75% | -9.4% | 1.12% | 1.26% |
| Net Income | -182.22M | -190.67M | -285.4M | -215.52M | -236.46M | -278.02M | -199.43M | 872.13M | -55.19M | -56.42M |
| Net Margin % | -4.33% | -3.92% | -18.55% | -3.57% | -3.22% | -3.87% | -3.61% | 16.99% | -0.96% | -0.88% |
| Net Income Growth % | 0.23% | -0.05% | -0.5% | 0.24% | -0.1% | -0.18% | 0.28% | 5.37% | -1.06% | -0.02% |
| Net Income (Continuing) | -182.22M | -190.67M | -285.4M | -215.52M | -236.46M | -294.82M | -265.07M | -92.82M | -55.19M | -56.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 16.81M | 65.64M | 964.96M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.34 | -4.26 | -5.45 | -3.99 | -4.25 | -4.46 | -2.87 | -1.26 | -1.00 | -1.15 |
| EPS Growth % | 0.28% | 0.2% | -0.28% | 0.27% | -0.07% | -0.05% | 0.36% | 0.56% | 0.21% | -0.15% |
| EPS (Basic) | -5.34 | -4.26 | -5.45 | -3.99 | -4.25 | -4.46 | -2.87 | -1.26 | -1.00 | -1.15 |
| Diluted Shares Outstanding | 34.15M | 44.71M | 52.35M | 53.97M | 55.61M | 62.34M | 69.46M | 73.59M | 55.3M | 48.85M |
| Basic Shares Outstanding | 34.15M | 44.71M | 52.35M | 53.97M | 55.61M | 62.34M | 69.46M | 73.59M | 55.3M | 48.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 237.47M | 528.5M | 378.75M | 532.82M | 338.49M | 393.34M | 249.87M | 353.46M | 133.54M | 161.07M |
| Cash & Short-Term Investments | 172.43M | 501.1M | 348.57M | 505.28M | 280.83M | 292.94M | 173.47M | 327.48M | 102.43M | 88.35M |
| Cash Only | 112.71M | 344.71M | 88.98M | 378.02M | 58.06M | 81.47M | 89.96M | 298.17M | 39.55M | 37.8M |
| Short-Term Investments | 59.73M | 156.39M | 259.59M | 127.25M | 222.77M | 211.47M | 83.51M | 29.31M | 62.88M | 50.55M |
| Accounts Receivable | 37.15M | 9.72M | 9.36M | 10.67M | 50.57M | 69.67M | 57.6M | 16.79M | 17.47M | 68.44M |
| Days Sales Outstanding | 321.92 | 72.94 | 222.09 | 64.53 | 251.42 | 353.88 | 380.1 | 119.32 | 111.07 | 388.01 |
| Inventory | 10.01M | 12.22M | 16.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 784.16 | 1.54K | 1.02K | - | - | - | - | - | - | - |
| Other Current Assets | 5.12M | 2.4M | 3.7M | 0 | 7.09M | 10.36M | 8.56M | 7.68M | 11.6M | 4.2M |
| Total Non-Current Assets | 62.64M | 110.75M | 62.65M | 27.41M | 70.34M | 75.72M | 124.95M | 253.94M | 248.46M | 193.09M |
| Property, Plant & Equipment | 9.87M | 8.46M | 10.16M | 13.18M | 59.25M | 59.68M | 53.35M | 52M | 45.35M | 35.77M |
| Fixed Asset Turnover | 4.27x | 5.75x | 1.51x | 4.58x | 1.24x | 1.20x | 1.04x | 0.99x | 1.27x | 1.80x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 50.86M | 91.56M | 41.59M | 11.87M | 9.5M | 833K | 68.37M | 0 | 0 | 0 |
| Other Non-Current Assets | 1.91M | 10.73M | 10.91M | 2.37M | 1.59M | 15.2M | 3.23M | 201.94M | 203.1M | 157.32M |
| Total Assets | 300.12M | 639.25M | 441.4M | 560.24M | 408.83M | 469.06M | 374.82M | 607.4M | 382M | 354.16M |
| Asset Turnover | 0.14x | 0.08x | 0.03x | 0.11x | 0.18x | 0.15x | 0.15x | 0.08x | 0.15x | 0.18x |
| Asset Growth % | -0.11% | 1.13% | -0.31% | 0.27% | -0.27% | 0.15% | -0.2% | 0.62% | -0.37% | -0.07% |
| Total Current Liabilities | 49.47M | 49.27M | 62.55M | 98.55M | 111.7M | 123.57M | 58.59M | 28.71M | 24.77M | 32.09M |
| Accounts Payable | 18.8M | 1.73M | 5.92M | 9.03M | 4.76M | 6.78M | 3.1M | 1.55M | 1.52M | 2.24M |
| Days Payables Outstanding | 1.47K | 218.57 | 358.58 | 4.61K | - | - | 5.84 | 8.95 | 13.69 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 17.61M | 29.2M | 17.44M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 144K | 152K | 125K | 1000K | 1000K | 1000K | 98K | 24K | 0 | 0 |
| Other Current Liabilities | 19.66M | 33.36M | 32.37M | 22.32M | 29.58M | 40.83M | 25.15M | -24K | 12.88M | 0 |
| Current Ratio | 4.80x | 10.73x | 6.05x | 5.41x | 3.03x | 3.18x | 4.26x | 12.31x | 5.39x | 5.02x |
| Quick Ratio | 4.60x | 10.48x | 5.79x | 5.41x | 3.03x | 3.18x | 4.26x | 12.31x | 5.39x | 5.02x |
| Cash Conversion Cycle | -367.72 | 1.4K | 882.24 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7.58M | 239.75M | 263.67M | 513.27M | 520.96M | 649.24M | 654.8M | 136.88M | 144.24M | 146.53M |
| Long-Term Debt | 0 | 222.68M | 223.75M | 454.35M | 445.19M | 599.84M | 599.39M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 47.73M | 47.22M | 52.68M | 45.41M | 45.24M | 39.11M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -26.18M | 0 | 0 | 240K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.58M | 17.08M | 39.92M | 32.74M | 21.29M | 1.83M | 2.18M | 91.29M | 99M | 107.42M |
| Total Liabilities | 57.05M | 289.02M | 326.22M | 611.82M | 632.67M | 772.81M | 713.39M | 165.6M | 169M | 178.62M |
| Total Debt | 0 | 222.68M | 223.75M | 454.35M | 510.53M | 676.26M | 669.52M | 52.16M | 49.16M | 49.82M |
| Net Debt | -112.71M | -122.03M | 134.77M | 76.33M | 452.46M | 594.79M | 579.56M | -246.01M | 9.61M | 12.02M |
| Debt / Equity | - | 0.64x | 1.94x | - | - | - | - | 0.12x | 0.23x | 0.28x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -128.54x | -30.43x | -22.78x | -7.91x | -34.82x | -30.16x | -14.44x | -23.84x | -18.44x |
| Total Equity | 243.06M | 350.23M | 115.18M | -51.59M | -223.84M | -303.75M | -338.57M | 441.8M | 213M | 175.54M |
| Equity Growth % | -0.16% | 0.44% | -0.67% | -1.45% | -3.34% | -0.36% | -0.11% | 2.3% | -0.52% | -0.18% |
| Book Value per Share | 7.12 | 7.83 | 2.20 | -0.96 | -4.03 | -4.87 | -4.87 | 6.00 | 3.85 | 3.59 |
| Total Shareholders' Equity | 243.06M | 350.23M | 115.18M | -51.59M | -223.84M | -303.75M | -338.57M | 441.8M | 213M | 175.54M |
| Common Stock | 0 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 0 | 0 |
| Retained Earnings | -321.56M | -512.23M | -797.74M | -1.01B | -1.25B | -1.53B | -1.73B | -853.91M | -909.1M | -965.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -70K | -253K | -733K | -166K | 145K | 47K | 0 | -15K | -65K | 7K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -168.86M | -98.99M | -201.05M | -112.87M | -238.2M | -250.4M | -207.86M | -186.99M | -27M | -11.54M |
| Operating CF Margin % | -4.01% | -2.03% | -13.07% | -1.87% | -3.24% | -3.48% | -3.76% | -3.64% | -0.47% | -0.18% |
| Operating CF Growth % | 0.04% | 0.41% | -1.03% | 0.44% | -1.11% | -0.05% | 0.17% | 0.1% | 0.86% | 0.57% |
| Net Income | -182.22M | -190.67M | -285.4M | -215.52M | -236.46M | -294.82M | -265.07M | -92.82M | -55.19M | -56.42M |
| Depreciation & Amortization | 2.99M | 3.12M | 4.03M | 3.17M | 6.21M | 6.97M | 8.6M | 7.02M | 4.26M | 3.62M |
| Stock-Based Compensation | 54.05M | 41.17M | 49.15M | 51.31M | 60.45M | 62.98M | 62.06M | 39.73M | 25.37M | 21.39M |
| Deferred Taxes | 2.17M | 282K | 8.74M | -11.21M | 0 | 0 | 0 | 0 | 3.21M | -7.57M |
| Other Non-Cash Items | -8.06M | 182K | 10K | -43K | -23.01M | 12.25M | 26.1M | -183.28M | 3.7M | 7.09M |
| Working Capital Changes | -37.78M | 46.93M | 22.43M | 59.43M | -45.4M | -37.78M | -39.55M | 42.35M | -8.34M | 20.36M |
| Change in Receivables | -1.63M | 1.28M | -1.61M | 1.63M | -15.02M | 6.13M | 1.8M | -2.72M | 0 | -966K |
| Change in Inventory | 1.03M | -3.18M | -7.3M | -1.63M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 8.72M | -16.44M | 3.8M | 3.58M | -4.27M | 3.66M | -3.53M | -1.61M | 6K | 750K |
| Cash from Investing | 111.04M | -148.24M | -56.33M | 176.71M | -83.05M | 10.72M | 124.49M | 1.15B | -32.7M | 12.28M |
| Capital Expenditures | -2.65M | -2.13M | -2.41M | -7.24M | -3.18M | -6.62M | -3.41M | -572K | -2.49M | -332K |
| CapEx % of Revenue | 0.06% | 0.04% | 0.16% | 0.12% | 0.04% | 0.09% | 0.06% | 0.01% | 0.04% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 113.69M | -146.1M | -53.93M | 17K | 5K | 64K | 6K | 1.1B | 1.51M | 0 |
| Cash from Financing | 81.31M | 479.23M | 1.66M | 225.2M | 1.29M | 263.08M | 91.86M | -758.81M | -198.93M | -2.5M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 3.05M | 7.57M | 10.22M | 5.57M | 6.62M | -11.73M | 3.47M | 5.08M | 618K | 508K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -171.5M | -101.12M | -203.46M | -120.11M | -241.37M | -257.02M | -211.26M | -187.56M | -29.48M | -11.87M |
| FCF Margin % | -4.07% | -2.08% | -13.22% | -1.99% | -3.29% | -3.58% | -3.82% | -3.65% | -0.51% | -0.18% |
| FCF Growth % | 0.04% | 0.41% | -1.01% | 0.41% | -1.01% | -0.06% | 0.18% | 0.11% | 0.84% | 0.6% |
| FCF per Share | -5.02 | -2.26 | -3.89 | -2.23 | -4.34 | -4.12 | -3.04 | -2.55 | -0.53 | -0.24 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.52x | 0.70x | 0.52x | 1.01x | 0.90x | 1.04x | -0.21x | 0.49x | 0.20x |
| Interest Paid | 0 | 0 | 7.45M | 7.47M | 26.18M | 24.02M | 39.03M | 22.24M | 0 | 0 |
| Taxes Paid | 13.39M | 9.49M | 4.93M | -7.32M | 22K | 14K | 0 | 117.97M | 24K | 109K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -68.39% | -64.27% | -122.65% | -677.87% | - | - | - | 1689.74% | -16.86% | -29.04% |
| Return on Invested Capital (ROIC) | -82.45% | -75.5% | -81.6% | -130.38% | -149.14% | -85.91% | -72.68% | -31.58% | -20.09% | -17.17% |
| Gross Margin | 88.95% | 94.05% | 60.81% | 98.82% | 100% | 100% | -250.12% | -23.46% | 29.26% | 100% |
| Net Margin | -432.56% | -391.94% | -1854.97% | -357.01% | -322.08% | -386.9% | -360.55% | 1698.54% | -96.11% | -87.63% |
| Debt / Equity | - | 0.64x | 1.94x | - | - | - | - | 0.12x | 0.23x | 0.28x |
| Interest Coverage | - | -128.54x | -30.43x | -22.78x | -7.91x | -34.82x | -30.16x | -14.44x | -23.84x | -18.44x |
| FCF Conversion | 0.93x | 0.52x | 0.70x | 0.52x | 1.01x | 0.90x | 1.04x | -0.21x | 0.49x | 0.20x |
| Revenue Growth | 260.42% | 15.48% | -68.37% | 292.37% | 21.61% | -2.12% | -23.03% | -7.17% | 11.84% | 12.12% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| YUPELRI Monotherapy | - | - | - | - | - | - | - | 19.5M | 77.34M | 83.52M |
| YUPELRI Monotherapy Growth | - | - | - | - | - | - | - | - | 296.70% | 7.99% |
| Collaboration revenue | - | - | - | - | - | - | - | 48.65M | 57.21M | 64.38M |
| Collaboration revenue Growth | - | - | - | - | - | - | - | - | 17.58% | 12.54% |
| Viatris collaboration agreement | - | - | - | - | - | - | 43.85M | 48.62M | - | - |
| Viatris collaboration agreement Growth | - | - | - | - | - | - | - | 10.89% | - | - |
| Licensing revenue | - | - | - | - | - | - | - | 2.5M | - | - |
| Licensing revenue Growth | - | - | - | - | - | - | - | - | - | - |
| Collaborative revenue | - | - | - | - | - | - | 11.46M | - | - | - |
| Collaborative revenue Growth | - | - | - | - | - | - | - | - | - | - |
| Co Promote Agreement | - | - | - | 3.27M | 13.66M | 43.89M | - | - | - | - |
| Co Promote Agreement Growth | - | - | - | - | 317.22% | 221.23% | - | - | - | - |
| Collaborative Arrangement Revenue | - | - | - | 41.79M | 31.25M | 26.46M | - | - | - | - |
| Collaborative Arrangement Revenue Growth | - | - | - | - | -25.22% | -15.32% | - | - | - | - |
| License | - | - | - | - | 28.5M | 1.5M | - | - | - | - |
| License Growth | - | - | - | - | - | -94.74% | - | - | - | - |
| Product | - | - | - | 15.3M | - | - | - | - | - | - |
| Product Growth | - | - | - | - | - | - | - | - | - | - |
| Ns5a Inhibitor | - | 15.1M | - | - | - | - | - | - | - | - |
| Ns5a Inhibitor Growth | - | - | - | - | - | - | - | - | - | - |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | - | - | - | - | - | - | 55.27M | 51.12M | 57.2M | 64.38M |
| United States Growth | - | - | - | - | - | - | - | -7.51% | 11.89% | 12.55% |
| Europe | 21.35M | 15.21M | 1.11M | 11.12M | 18.65M | 1.54M | 38K | 222K | 223K | - |
| Europe Growth | - | -28.77% | -92.71% | 902.43% | 67.80% | -91.76% | -97.53% | 484.21% | 0.45% | - |
| U | 16.98M | 33.18M | 14.27M | 49.24M | 54.76M | 70.32M | - | - | - | - |
| U Growth | - | 95.39% | -56.98% | 245.00% | 11.21% | 28.41% | - | - | - | - |
| Asia | 2.9M | 254K | 5K | 14K | - | - | - | - | - | - |
| Asia Growth | - | -91.25% | -98.03% | 180.00% | - | - | - | - | - | - |
| Other Regions | 889K | 4K | - | - | - | - | - | - | - | - |
| Other Regions Growth | - | -99.55% | - | - | - | - | - | - | - | - |
Theravance Biopharma, Inc. (TBPH) reported $80.3M in revenue for fiscal year 2024. This represents a 441% increase from $14.9M in 2011.
Theravance Biopharma, Inc. (TBPH) grew revenue by 12.1% over the past year. This is steady growth.
Yes, Theravance Biopharma, Inc. (TBPH) is profitable, generating $29.3M in net income for fiscal year 2024 (-87.6% net margin).
Theravance Biopharma, Inc. (TBPH) has a return on equity (ROE) of -29.0%. Negative ROE indicates the company is unprofitable.
Theravance Biopharma, Inc. (TBPH) generated $243.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.